-
Nov 10, 2024 | 
blog.furrend.xyz | Jun Gong
Hello Furrend #29 — Meet Phoenix @wasabi.sushi.matchaWelcome to “Hello Furrend,” our weekly content series to spotlight some of the most inspiring pet content creators in the Furrend community. If you’re a pet content creator and want to be featured, please reach out to us at [email protected], and you could be our next furrend in the series.
-
Oct 14, 2024 | 
blog.furrend.xyz | Jun Gong
From mental health to social media stars — why pets and the pet industry are more important than everThree weeks ago, we caught up with Fiona Bowler, a historian of World War II and Cold War history and the proud pet parent of Reg, a mischievous cat who decided to cause a little chaos in the middle of our chat.
-
Aug 22, 2024 | 
blog.furrend.xyz | Jun Gong
Hello Furrend #22 — Meet Jonathan Wolfe🐱Welcome to “Hello Furrend,” our weekly content series to spotlight some of the most inspiring pet content creators in the Furrend community. If you’re a pet content creator and want to be featured, please reach out to us at [email protected], and you could be our next furrend in the series. Jonathan Wolfe (@jonathanwwolfe) is a Canada-based artist with a talent for blending wit and humor into his work.
-
Jul 25, 2024 | 
onclive.com | Jun Gong
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, discusses the benefits and limitations of treatment with PARP inhibitor–based regimens for patients with metastatic castration-resistant prostate cancer (mCRPC), as well as common adverse effects (AEs) associated with these agents.
-
Jul 15, 2024 | 
onclive.com | Jun Gong
CommentaryVideoJuly 15, 2024Jun Gong, MD, discusses the importance of molecular profiling when determining optimal treatments for patients with mCRPC.
-
Jun 28, 2024 | 
onclive.com | Jun Gong
CommentaryVideoJune 28, 2024Jun Gong, MD, discusses the variety of PARP inhibitor–based frontline treatment regimens that are FDA approved for patients with mCRPC.
-
Feb 20, 2024 | 
onclive.com | Jun Gong
Jun Gong, MD, medical director, Colorectal Cancer; associate professor, medicine; medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Cancer, discusses the significance of the phase 3 EMBARK study (NCT02319837) investigating enzalutamide (Xtandi) in nonmetastatic castration-sensitive prostate cancer (nmCSPC).
-
Feb 7, 2024 | 
onclive.com | Jun Gong
Jun Gong, MD, medical director, Colorectal Cancer; associate professor, medicine; medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Cancer, discusses the current treatment armamentarium for patients with metastatic hormone-sensitive prostate cancer (mHSPC), highlighting the use of triplet therapeutic options.
-
Jan 29, 2024 | 
onclive.com | Jun Gong
Jun Gong, MD, medical director, Colorectal Cancer; associate professor, medicine; medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Cancer, discusses efforts to address unmet needs in metastatic hormone-sensitive prostate cancer (mHSPC) through ongoing biomarker research and real-world analysis of triplet therapy integration in clinical practice.
-
Nov 14, 2023 | 
nature.com | Jun Gong |Michael Freeman |Leigh Ellis |Dan Theodorescu
AbstractBlack men with prostate cancer have historically had worse outcomes than white men with prostate cancer. The causes of this disparity in outcomes are multi-factorial, but a potential basis is that prostate cancers in Black men are biologically distinct from prostate cancers in white men.
